NTRK3 receptor expression is strictly associated with medullary thyroid cancer RET mutation status

2014 ◽  
Author(s):  
Malgorzata Oczko-Wojciechowska ◽  
Michal Swierniak ◽  
Malgorzata Kowalska ◽  
Agnieszka Pawlaczek ◽  
Monika Kowal ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Medullary Thyroid Cancer ◽  
Receptor Expression ◽  
Mutation Status ◽  
Medullary Thyroid ◽  
Ret Mutation

scholarly journals Cabozantinib in Progressive Medullary Thyroid Cancer

2013 ◽  
Vol 31 (29) ◽  
pp. 3639-3646 ◽  
Author(s):  
Rossella Elisei ◽  
Martin J. Schlumberger ◽  
Stefan P. Müller ◽  
Patrick Schöffski ◽  
Marcia S. Brose ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Growth Factor ◽  
Adverse Events ◽  
Medullary Thyroid Cancer ◽  
Response Rate ◽  
Growth Factor Receptor ◽  
Phase Iii ◽  
Mutation Status ◽  
Medullary Thyroid ◽  
Ret Mutation

PurposeCabozantinib, a tyrosine kinase inhibitor (TKI) of hepatocyte growth factor receptor (MET), vascular endothelial growth factor receptor 2, and rearranged during transfection (RET), demonstrated clinical activity in patients with medullary thyroid cancer (MTC) in phase I.Patients and MethodsWe conducted a double-blind, phase III trial comparing cabozantinib with placebo in 330 patients with documented radiographic progression of metastatic MTC. Patients were randomly assigned (2:1) to cabozantinib (140 mg per day) or placebo. The primary end point was progression-free survival (PFS). Additional outcome measures included tumor response rate, overall survival, and safety.ResultsThe estimated median PFS was 11.2 months for cabozantinib versus 4.0 months for placebo (hazard ratio, 0.28; 95% CI, 0.19 to 0.40; P < .001). Prolonged PFS with cabozantinib was observed across all subgroups including by age, prior TKI treatment, and RET mutation status (hereditary or sporadic). Response rate was 28% for cabozantinib and 0% for placebo; responses were seen regardless of RET mutation status. Kaplan-Meier estimates of patients alive and progression-free at 1 year are 47.3% for cabozantinib and 7.2% for placebo. Common cabozantinib-associated adverse events included diarrhea, palmar-plantar erythrodysesthesia, decreased weight and appetite, nausea, and fatigue and resulted in dose reductions in 79% and holds in 65% of patients. Adverse events led to treatment discontinuation in 16% of cabozantinib-treated patients and in 8% of placebo-treated patients.ConclusionCabozantinib (140 mg per day) achieved a statistically significant improvement of PFS in patients with progressive metastatic MTC and represents an important new treatment option for patients with this rare disease. This dose of cabozantinib was associated with significant but manageable toxicity.

LOW PREVALENCE OF THE SOMATIC M918T RET MUTATION IN MICRO-MEDULLARY THYROID CANCER

Thyroid ◽  
2012 ◽  
pp. 120110140236009
Author(s):  
cristina romei ◽  
Clara Ugolini ◽  
Barbara Cosci ◽  
liborio torregrossa ◽  
Agnese Vivaldi ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Medullary Thyroid Cancer ◽  
Medullary Thyroid ◽  
Ret Mutation ◽  
Low Prevalence

Medullary Thyroid Cancer in a Patient with Hirschsprung Disease with a C609Y Germline RET-mutation

2005 ◽  
Vol 40 (2) ◽  
pp. 226-229 ◽  
Author(s):  
Jan Willem B. de Groot ◽  
Rolf H. Sijmons ◽  
Thera P. Links ◽  
John Tn. M. Plukker ◽  
Robert M. W. Hofstra
Keyword(s):  
Thyroid Cancer ◽  
Medullary Thyroid Cancer ◽  
Hirschsprung Disease ◽  
Medullary Thyroid ◽  
Ret Mutation
Sign in / Sign up

Export Citation Format

Share Document